Search Results
Jul 15, 2025, 08:03 ET Food Supply Security Becomes QuantiPath Under Bold Rebrand
strategy designed to reflect both the scientific rigor and forward-thinking energy of the company. The updated name, logo, and iconography emphasize the DNA-level precision and security the company provides to the food industry — protecting what ultimately ends up on the plate. The new brand also introduces
More news about: QuantiPath
Jul 15, 2025, 08:00 ET EVERSANA Announces Enterprise Advancement to 'Pharmatize AI" With the Launch of the EVERSANA AI Accelerator
operations. "Innovation isn't new to EVERSANA. From our COMPLETE Commercialization model to the use of agentic KOL influencers, evolution is in our DNA. Today, we give that spirit of transformation a home in our global enterprise," added Lang. "We invite our clients and partners to collaborate and build
More news about: EVERSANA
Jul 15, 2025, 08:00 ET Topgolf Added Field Goal Posts - Now It Needs a Dad to Inspect Them
Terms and conditions apply. What They Said"At Topgolf, play and friendly competition are in our DNA, which is why we're excited to blend golf with football just as training camps fire up," said Topgolf CEO Artie Starrs.
More news about: Topgolf
Jul 14, 2025, 09:00 ET JUICY COUTURE FRAGRANCES LAUNCHES JUST MOI, A NEW PRESTIGE EAU DE PARFUM FOR THE BOLD AND UNAPOLOGETICALLY AUTHENTIC
Just Moi embraces a new generation of beauty consumers, while staying true to the DNA of Juicy Couture Fragrances NEW YORK, July 14, 2025
More news about: Juicy Couture Fragrances
Jul 14, 2025, 09:00 ET Arrive AI selects Synoptek as a Strategic IT Partner
companies optimize their IT environments and enable innovation through technology. With growth, ownership, inclusiveness, and philanthropy embedded in its DNA, Synoptek is committed to delivering improved business results and unmatched service to all its stakeholders. Cautionary Note Regarding Forward
More news about: Arrive AI
Jul 14, 2025, 08:30 ET Viome and Scripps Research Partner to Develop First At-home RNA Screening Test to Prevent Colon Cancer Before It Strikes
cancerous. Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions. BELLEVUE, Wash.
More news about: Viome Life Sciences
Jul 14, 2025, 03:00 ET Bridge Capture™ 在結直腸癌試點中實現靈敏兼可擴展的液體活檢
為高度便利的癌症診斷技術。」 Bridge Capture™ 是 Genomill 多個 Geno1® 技術的體現，而該等技術是基於環狀 DNA 和線性 DNA 擴增。技術總監兼該技術的發明者 Juha-Pekka Pursiheimo 補充：「Bridge Capture 透過使用環狀單股 DNA，為 NGS 庫設計建立新標準——較傳統線性庫更靈活兼更強大的替代方案。結合我們的無 PCR DNA 擴增方法，為 Genomill 徹底改變 NGS 庫製備作定位。 」 該完整研究（標題為「Bridge Capture 技術在轉移性結直腸癌患者液體活檢突變分析的評估
More news about: Genomill Health
Jul 14, 2025, 03:00 ET Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Geno1® technologies that are based on circular DNA and linear DNA amplification. Juha-Pekka Pursiheimo, CTO and inventor of the technology, added: "Bridge Capture establishes a new standard for NGS library design by using circular single-stranded DNA - a more flexible and robust alternative to traditional
More news about: Genomill Health
Jul 14, 2025, 03:00 ET Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Geno1® technologies that are based on circular DNA and linear DNA amplification. Juha-Pekka Pursiheimo, CTO and inventor of the technology, added: "Bridge Capture establishes a new standard for NGS library design by using circular single-stranded DNA - a more flexible and robust alternative to traditional
More news about: Genomill Health
Jul 14, 2025, 03:00 ET Bridge Capture™ ermöglicht empfindliche, skalierbare Flüssigbiopsie in Darmkrebs-Pilotprojekten
Genomill, die auf zirkulärer DNA und linearer DNA-Amplifikation beruhen. Juha-Pekka Pursiheimo, Technologievorstand und Erfinder der Technologie, fügte hinzu: "Bridge Capture setzt einen neuen Standard für das Design von NGS-Bibliotheken, indem es zirkuläre einzelsträngige DNA verwendet – eine flexiblere
More news about: Genomill Health
Jul 14, 2025, 03:00 ET Bridge Capture™ possibilita biópsia líquida sensível e escalável em um estudo piloto sobre câncer colorretal
tecnologias Geno1® da Genomill que se baseiam no DNA circular e na amplificação linear do DNA. Juha-Pekka Pursiheimo, CTO e criador da tecnologia, acrescentou: "A Bridge Capture estabelece um novo padrão para o design de bibliotecas NGS usando DNA de fita simples circular - uma alternativa mais flexível
More news about: Genomill Health
Jul 14, 2025, 03:00 ET Bridge Capture™, 대장암 액체 생검 파일럿 연구에서 확장 가능한 고감도 분석 기술 입증
강조했다.Bridge Capture는 원형 DNA 및 선형 DNA 증폭을 기반으로 한 지노밀의 Geno1® 기술을 구현한 사례다. 유하-페카 푸르시헤이모(Juha-Pekka Pursiheimo) 기술 개발자이자 최고기술책임자(CTO)는 "Bridge Capture는 기존 선형 라이브러리에 비해 훨씬 유연하고 강력한 대안인 원형 단일 가닥 DNA를 사용하여 NGS 라이브러리 설계의 새로운 기준을 제시한다. 당사의 PCR-free DNA 증폭 기술과 결합하면, 지노밀은 NGS 라이브러리 전처리 방식에
More news about: Genomill Health
Jul 10, 2025, 17:31 ET Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight
antibody conjugated to the alpha-emitting radionuclide actinium-225. This targeted delivery of alpha radiation to GPC3-positive cancer cells can cause DNA double-strand breaks, potentially decreasing cell viability and exerting anti-tumor effects. The anticipated launch of these emerging therapies
More news about: DelveInsight Business Research, LLP
Jul 10, 2025, 16:05 ET Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025
About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jul 10, 2025, 15:51 ET SunsolveMD by TheSolveMD and Elsa Hosk Redefine Sun Protection with In-House Biotech Innovation
Platform: Where Biotech Meets Beauty At the core of SunsolveMD by TheSolveMD is SolveDNAReverse™, a patented complex designed to preserve DNA integrity and support cellular repair in skin exposed to UV, pollution, and oxidative stress. The SolveTech™ innovation stack also includes:
More news about: SunSolve MD
Jul 10, 2025, 13:00 ET Meet Us in Ibiza: EDITION and El Silencio Present the Summer EDITION, an Exclusive Poolside Pop-Up this August
thoughtfully crafted playlist from morning to sunset, blending EDITION's signature sound with El Silencio's musical DNA, capturing the energy of both brands. The co-branded pool area will also feature custom, luxurious towels, pillows, and pool floats, alongside a cart
More news about: Marriott International, Inc.
Jul 10, 2025, 09:15 ET Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year
Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in
More news about: Illumina, Inc.
Jul 10, 2025, 09:00 ET Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current 'Wait and See' Approach
feasibility of intervention at this precursor stage. Inqovi—an oral drug currently FDA-approved to treat a related blood cancer—works by altering the DNA of abnormal blood cells, thus slowing their growth and reducing the risk of progression to more advanced disease stages. The two-arm study will
More news about: Break Through Cancer
Jul 10, 2025, 08:54 ET LG Debuts Next-Generation Precision Medical AI
prognosis, oncology drug development, and personalized treatment selection. 'EXAONE Path 2.0' was trained using multi-omics data, including both DNA and RNA, enabling it to interpret pathology images and underlying biological processes while integrating genetic insights vital to disease research and
More news about: LG AI RESEARCH
Jul 10, 2025, 08:29 ET Cellecta, Inc. Expands Immune Profiling Portfolio with DriverMap™ Single-Cell AIR Kits for Affordable, High-Resolution Chain-Pairing of T-Cell and B-Cell Receptors
The DriverMap scAIR TCR-BCR assays are the latest addition to an extensive DriverMap AIR product and service offering, which also includes bulk AIR DNA and RNA kits and services, spike-in standards, and downstream bioinformatics analysis. More information on the scAIR assays is available at cellecta.com/scAIR-kits
More news about: Cellecta Inc.
Jul 10, 2025, 05:00 ET Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly
More news about: Klotho Neurosciences, Inc.
Jul 10, 2025, 03:00 ET NETSCOUT Earns Frost & Sullivan's 2025 MENA Technology Innovation Leadership Recognition for Excellence in Cybersecurity Solutions
scale advanced protection across enterprise, telecom, and edge environments across MENA and globally. Innovation is at the heart of NETSCOUT's DNA. Its suite of solutions—featuring Omnis Cyber Intelligence, Arbor DDoS Protection, and nGeniusONE—leverages adaptive machine learning to analyze real-time
More news about: Frost & Sullivan
Jul 10, 2025, 03:00 ET NETSCOUT Earns Frost & Sullivan's 2025 MENA Technology Innovation Leadership Recognition for Excellence in Cybersecurity Solutions
scale advanced protection across enterprise, telecom, and edge environments across MENA and globally. Innovation is at the heart of NETSCOUT's DNA. Its suite of solutions—featuring Omnis Cyber Intelligence, Arbor DDoS Protection, and nGeniusONE—leverages adaptive machine learning to analyze real-time
More news about: Frost & Sullivan
Jul 09, 2025, 16:00 ET Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia
Decitabine and Cedazuridine Fixed-Dose CombinationThis product is an orally administered, fixed dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine,5 an inhibitor of cytidine deaminase.6 By inhibiting cytidine deaminase
More news about: Taiho Oncology
Jul 09, 2025, 15:12 ET Black Dragon Capital℠ Deepens FinTech Leadership Roster with Addition of New Financial Services Advisors
Their Founder, Chairman and CEO, Louis Hernandez Jr. was the CEO of Open Solutions during the launch the market shaping DNA core product, and the founder of Payveris, and the rest of their team is familiar the technologies created for and by credit unions which are made more
More news about: Black Dragon Capital